MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Esperion Therapeutics ROE Ratio 2011-2026 | ESPR
Annual ROE Ratio Esperion Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.51 | 13.31 | 45.99 | 72.17 | 136.64 | 149.32 | -487.04 | -255.07 | -68.24 | -32.8 | -17.33 | -27.24 | -35.21 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 149.32 | -487.04 | -38.31 |
Quarterly ROE Ratio Esperion Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.34 | 38.39 | 14.72 | 15.29 | 20.74 | 21.47 | 60.95 | 69.63 | 78.94 | 64.26 | 83.39 | 83.78 | 75.39 | 67.24 | 175.91 | 245.66 | 101.68 | 149.32 | -269.86 | -701.47 | -843.64 | -487.04 | -252.42 | 27.24 | 241.22 | -255.07 | -194.67 | -150.07 | -109.98 | -68.24 | -65.43 | -54.56 | -42.99 | -32.8 | -24.7 | -21.54 | -19.72 | -17.33 | -19.84 | -22.73 | -25.33 | -27.24 | -33.23 | -32.96 | -35.39 | -35.21 | -15.42 | -0.25 | 16.74 | 22.47 | 15.76 | 7.65 | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 245.66 | -843.64 | -41.04 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.46 | 1.72 % | $ 1.03 B |  Canada |
 |
Altimmune
ALT
|
-39.17 | $ 3.47 | 3.89 % | $ 306 M |  USA |
 |
Amgen
AMGN
|
89.06 | $ 350.07 | 0.63 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 19.49 | -0.05 % | $ 911 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 220.18 | -0.77 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Aurinia Pharmaceuticals
AUPH
|
36.26 | $ 14.83 | 5.78 % | $ 1.99 B | Canada |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.42 | 3.64 % | $ 362 M | Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Axsome Therapeutics
AXSM
|
-207.46 | $ 154.69 | -1.42 % | $ 7.7 B | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
5.73 | $ 54.66 | 0.97 % | $ 10.5 B | USA |
 |
Benitec Biopharma
BNTC
|
-9.05 | $ 11.25 | 2.46 % | $ 463 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-53.8 | $ 12.74 | - | $ 768 M | USA |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.59 | 4.28 % | $ 186 M | USA |
 |
Calithera Biosciences
CALA
|
-1373.04 | - | -10.95 % | $ 876 K | USA |
 |
Cellectis S.A.
CLLS
|
-26.25 | $ 3.38 | 1.05 % | $ 116 M | France |
 |
Cara Therapeutics
CARA
|
-207.61 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
94.87 | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
34.4 | $ 2.13 | 1.9 % | $ 199 M | Israel |
 |
Denali Therapeutics
DNLI
|
-34.38 | $ 20.96 | 3.89 % | $ 3.45 B | USA |
 |
Dyadic International
DYAI
|
-115.6 | $ 0.86 | -8.51 % | $ 24.8 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
CorMedix
CRMD
|
40.23 | $ 6.33 | 1.28 % | $ 456 K | USA |